Prevention & lipids

Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial

CirculationPublished prespecified second randomization of the randomized Ez-PAVE trial

Primary result · Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or hospitalization for unstable anginaResult — go to the resultHazard ratio 1.07 95% CI 0.83–1.37

Authors' conclusion

Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target.

Study context

Population
Patients with atherosclerotic cardiovascular disease, enrolled between January 2021 and July 2022, first randomized to an intensive (<55 mg/dL) or conventional (<70 mg/dL) low-density lipoprotein cholesterol (LDL-C)-targeting strategy
Participants
3,048 patients
Comparison
Initial statin-ezetimibe combination therapy versus statin monotherapy
  • Statin-ezetimibe combination therapyn = 1,525
  • Statin monotherapyn = 1,523reference
Primary endpoint
Composite of:
  • Death from cardiovascular causes
  • Nonfatal myocardial infarction
  • Nonfatal stroke
  • Any revascularization
  • Hospitalization for unstable angina
Follow-up
3 years
Methodological details17 centers in South Korea
  • 17 centers in South Korea

Primary result

As reported in the abstract

Composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, any revascularization…

Hazard ratio

1.07

95% CI 0.83–1.37

P = 0.596

Events by treatment group

Statin-ezetimibe combination therapyvs Statin monotherapy
HR 1.07 (95% CI 0.83–1.37); P = 0.596

Further findings

Median LDL-C during follow-up, intensive-targeting strategy

Median LDL-C during follow-up, conventional-targeting strategy

Ezetimibe added during follow-up among patients initially on statin monotherapy

Patients

Intensive-targeting strategy, of those initially on statin monotherapy
241 (34.3%)
Conventional-targeting strategy, of those initially on statin monotherapy
177 (24.8%)

Treatment effect of intensive- vs conventional-targeting strategies by therapy regimen

Consistent regardless of therapy regimens without significant heterogeneity
  • P interaction =0.583

Original publication

Statin–Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial. Circulation. Published 7 November 2026. doi:10.1161/circulationaha.126.083811

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.